Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ08AJ)

Drug Name

Edotreotide Drug Info

Synonyms

Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 158782
ChEBI ID: CHEMBL408350
CAS Number: CAS 204318-14-9
TTD Drug ID: DMQ08AJ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Somatostatin receptor (SSTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
177Lu-DOTA-octreotate	DMP5L8S	Melanoma	2C30	Phase 3	[3]
177-Lu-oxodotreotide	DMMZS2T	Neuroendocrine cancer	2B72.1	Phase 3	[4]
177Lu-DOTATATE	DMT8GVU	Hepatitis C virus infection	1E51.1	Phase 2	[3]
Somatoprim	DMTVS3A	Acromegaly	5A60.0	Phase 2	[5]
FK-962	DMV0MZ3	Alzheimer disease	8A20	Phase 2	[6]
177Lu-labelled DOTA-JR11	DMVZ9XL	Neuroendocrine cancer	2B72.1	Phase 1/2	[7]
212Pb-labelled DOTAMTATE	DMN9MPX	Neuroendocrine cancer	2B72.1	Phase 1	[8]
AlphaMedix	DMBVM1Q	Neuroendocrine cancer	2B72.1	Phase 1	[9]
FK-960	DMPD8O2	Cognitive impairment	6D71	Discontinued in Phase 2	[6]
SEGLITIDE	DMXZVPH	Pain	MG30-MG3Z	Discontinued in Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor (SSTR)	TTOMNR9	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5638).
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
4	Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
5	DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
6	FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
7	Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
8	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
9	Clinical pipeline report, company report or official report of Orano Med.
10	Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.